Table 4.
Subgroup analyses of SBP in clinically meaningful subsets.
| Groups | Number of patients | Events | Crude | p for interaction | Adjusted * | p for interaction | ||
|---|---|---|---|---|---|---|---|---|
| HR (95%CI) | p-value | HR (95%CI) | p-value | |||||
| Etiology | 0.442 | 0.560 | ||||||
| Organic TR | 686 | 51 | 0.92 (0.80–1.05) | 0.229 | 0.84 (0.72–0.98) | 0.031 | ||
| Functional TR | 1,025 | 78 | 0.91 (0.82–1.01) | 0.089 | 0.91 (0.82–1.01) | 0.064 | ||
| Other | 129 | 13 | 0.73 (0.51–1.04) | 0.078 | 0.78 (0.56–1.09) | 0.141 | ||
| NYHAc | 0.490 | 0.619 | ||||||
| NYHA < III | 1,300 | 54 | 0.99 (0.87–1.12) | 0.846 | 0.90 (0.78–1.04) | 0.168 | ||
| NYHA≥III | 548 | 111 | 0.93 (0.86–1.02) | 0.126 | 0.87 (0.78–0.96) | 0.007 | ||
| LVEF | 0.708 | 0.732 | ||||||
| LVEF <50 | 289 | 55 | 0.93 (0.84–1.01) | 0.100 | 0.90 (0.78–1.03) | 0.111 | ||
| LVEF≥50 | 1,559 | 110 | 0.95 (0.84–1.08) | 0.445 | 0.87 (0.78–0.97) | 0.011 | ||
| ACEI/ARB | 0.130 | 0.428 | ||||||
| Yes | 740 | 61 | 0.99 (0.88–1.10) | 0.807 | 0.92 (0.81–1.06) | 0.249 | ||
| No | 1,273 | 104 | 0.88 (0.79–0.97) | 0.013 | 0.86 (0.77–0.97) | 0.011 | ||
| Diuretic | 0.797 | 0.490 | ||||||
| Yes | 1,191 | 135 | 0.95 (0.87–1.03) | 0.186 | 0.87 (0.79–0.95) | 0.003 | ||
| No | 822 | 30 | 0.97 (0.82–1.16) | 0.751 | 0.93 (0.77–1.13) | 0.488 | ||
*
Adjusted for age, sex, BMI, diabetes, CAD, PH, eGFR, severe TR, LVEF, LVEDDi, NYHAc, and etiology when they were not the strata variables. BMI, body mass index; CAD, coronary heart disease; eGFR, estimated glomerular filtration rate; LVEDDi, indexed left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; PH, pulmonary hypertension; SBP, systolic blood pressure; TR, tricuspid regurgitation.